A systematic review and meta-analysis, published in 2012, identified 116 reports from 65 trials of antipsychotic therapy in patients with schizophrenia.[Leucht et al., 2012] This information amounted to data for 6,493 patients.[Leucht et al., 2012] The results demonstrated that maintenance antipsychotic therapy has benefits for patients, including reduced risk of relapse, improved quality of life, and reduced aggressive acts.[Leucht et al., 2012] However, the authors caution that the benefits of antipsychotics must be weighed against the risk of adverse events.[Leucht et al., 2012]
Reference:
Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379 (9831): 2063–2071.